Effects of recombinant human insulin-like growth factor I administration on spontaneous and growth hormone (GH)-releasing hormone-stimulated GH secretion in anorexia nervosa by L. Gianotti et al.
Effects of Recombinant Human Insulin-Like Growth
Factor I Administration on Spontaneous and Growth
Hormone (GH)-Releasing Hormone-Stimulated GH
Secretion in Anorexia Nervosa*
LAURA GIANOTTI, ANGELA I. PINCELLI, MASSIMO SCACCHI, MIMMA ROLLA,
DEANNA BELLITTI, EMANUELA ARVAT, FABIO LANFRANCO,
ANTONIO TORSELLO, EZIO GHIGO, FRANCO CAVAGNINI, AND
EUGENIO E. MU¨LLER
Division of Endocrinology (L.G., E.A., F.L., E.G.), Department of Internal Medicine, University of
Turin, 10126 Turin; Second Chair of Endocrinology (A.I.P., M.S., F.C.), University of Milan, San Luca
Hospital, 20149 Milano; Unit of Adolescentology (M.R., D.B.), University of Pisa, 56100 Pisa; and
Department of Pharmacology (A.T., E.E.M.), University of Milan, 20129 Milano, Italy
ABSTRACT
Exaggerated GH and reduced insulin-like growth factor I (IGF-I)
levels are common features in anorexia nervosa (AN). A reduction of
the negative IGF-I feedback could account, in part, for GH hyperse-
cretion. To ascertain this, we studied the effects of recombinant hu-
man (rh)IGF-I on spontaneous and GH-releasing hormone (GHRH)-
stimulated GH secretion in nine women with AN [body mass index,
14.1 6 0.6 kg/m2] and in weight matched controls (normal weight).
Mean basal GH concentrations (mGHc) and GHRH (2.0 mg/kg, iv)
stimulation were significantly higher in AN. rhIGF-I administration
(20 mg/kg, sc) significantly reduced mGHc in AN (P , 0.01), but not
normal weight, and inhibited peak GH response to GHRH in both
groups; mGHc and peak GH, however, persisted at a significantly
higher level in AN. Insulin, glucose, and IGFBP-1 basal levels were
similar in both groups. rhIGF-I inhibited insulin in AN, whereas
glucose remained unaffected in both groups. IGFBP-1 increased in
both groups (P , 0.05), with significantly higher levels in AN.
IGFBP-3 was under basal conditions at a lower level in AN (P , 0.05)
and remained unaffected by rhIGF-I. This study demonstrates that
a low rhIGF-I dose inhibits, but does not normalize, spontaneous and
GHRH-stimulated GH secretion in AN, pointing also to the existence
of a defective hypothalamic control of GH release. Moreover, the
increased IGFBP-1 levels might curtail the negative IGF-I feedback
in AN. (J Clin Endocrinol Metab 85: 2805–2809, 2000)
INSULIN-LIKE growth factor (IGF)-I exerts an inhibitoryfeedback action on GH secretion both in animals and in
humans (1–13). The negative IGF-I feedback may occur directly
at the pituitary, through activation of the IGF-I receptor, leading
to inhibition of GH synthesis and release (1–5). Alternatively,
indirect central nervous system-mediated mechanisms, such as
stimulation of hypothalamic SRIF and/or inhibition of GH-
releasing hormone (GHRH)-secreting neurons, have been hy-
pothesized (1, 11, 14, 15), though it has been suggested that
IGF-II coadministration is also needed to allow an inhibitory
effect on somatotroph secretion (16).
In anorexia nervosa (AN), as well as in malnutrition and
catabolic states, low IGF-I levels are generally coupled to GH
hypersecretion (17–22), denoting the existence of peripheral
GH resistance (20, 23). GH hypersecretion in AN would rest
on the reduction of the negative IGF-I feedback mechanism
(19, 21–23), as also implied by evidence that recombinant
human (rh)IGF-I, administered to subjects with GH hyper-
secretion, inhibits the secretion of GH (7, 8, 10, 24, 25).
Alternatively, GH hypersecretion in AN could be caused
by primary alteration in the neural control of somatotroph
function (17, 18, 22, 26–28). In fact, GH secretion in AN is
rather refractory to the inhibition exerted by cholinergic an-
tagonists (17, 18), as well as to the stimulation by cholinergic
agonists or b adrenergic antagonists (27, 28), effects which
are allegedly attributable to modulation of hypothalamic
SRIF release (29, 30).
The aim of the present study was to substantiate the view
that GH hypersecretion in AN occurs because of the lack of
adequate IGF-I feedback action. Were this the case, patients
with AN should present with normalization of both spon-
taneous and GHRH-stimulated GH secretion after pretreat-
ment with rhIGF-I.
Subjects and Methods
Drugs
Vials containing 1000 mg liophylized rhIGF-I were kindly provided by
Pharmacia & Upjohn, Inc. (Stockholm, Sweden). Vials containing 50 mg
GHRH-29 were kindly provided by Serono Laboratories, Inc. (Rome, Italy).
Study protocols
Nine female patients with AN (age, mean 6 sem, 24.0 6 1.4 yr; body
mass index, 14.1 6 0.6 kg/m2) took part in the study. Clinical and
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hormonal details of the patients are reported in Table 1. All AN patients
were in the acute phase of the illness and met the diagnostic criteria for
AN according to Diagnostic and Statistical Manual of Mental Disorders
IV (31).They were not under treatment with psychoactive drugs.
The results in AN were compared with those obtained in eight normal
young women (NW; age, 28.3 6 1.2 yr; body mass index, 20.1 6 0.5
kg/m2), studied in their early follicular phase (13).
All subjects gave an informed consent to participate in the study,
which had been approved by an independent ethical committee.
All subjects underwent the following tests at least 3 days apart: 1)
placebo (sc administration of isotonic saline at 0 min); 2) rhIGF-I ad-
ministration (20 mg/kg, sc at 0 min); 3) placebo1GHRH (2.0 mg/kg, iv
at 1180 min); and 4) rhIGF-I1GHRH.
The tests were begun at 0830–0900 h, after an overnight fast and 30
min after an indwelling catheter had been placed into an antecubital vein
of the forearm, kept patent by slow infusion of isotonic saline.
Blood samples were drawn basally at 0 min and then every 15 min
up to 1300 min.
Serum GH levels were measured at each time interval in all sessions.
Serum IGF-I, serum insulin, and plasma glucose levels were measured
basally and then every 30 min, up to 1300 min, in all sessions. Serum
IGFBP-1 and IGFBP-3 levels were measured basally and at 300 min in
sessions 1 and 2.
Serum GH levels (mg/L) were measured in duplicate by immu-
noradiometric assay (hGH-CTK IRMA, Sorin Biomedica, Saluggia,
Italy). The sensitivity of the assay was 0.15 mg/L. The inter- and
intraassay coefficients of variation were 2.9 – 4.5% and 2.4 – 4.0%,
respectively.
Serum IGF-I levels (mg/L) were measured in duplicate by RIA
(Nichols Institute Diagnostics, San Juan Capistrano, CA). All samples
were extracted with acid-ethanol to avoid interference by binding
proteins. The sensitivity of the assay was 0.1 mg/L. The inter- and
intraassay coefficients of variation were 10.1–15.7% and 7.6 –15.5%,
respectively.
Serum insulin levels (mU/L) were measured in duplicate by immu-
noradiometric assays (Sorin Biomedica). The sensitivity of the assay was
2.5 6 0.3 mU/L. Inter- and intraassay coefficients of variation were
between 6.2 and 10.8% and between 5.5 and 10.6%, respectively.
Plasma glucose levels (mg/dL) were measured by a glucose-oxidase
colorimetric method (GLUCOFIX, Menarini Diagnostics, Firenze, Italy).
Serum IGFBP-1 levels (ng/mL) were measured in duplicate by im-
munoradiometric assay provided by Diagnostics Systems Laboratories,
Inc., Webster, TX. The sensitivity of the assay was 0.33 ng/mL. The inter-
and intraassay coefficients of variation were between 3.5 and 6.0% and
between 2.7 and 5.2%, respectively.
Serum IGFBP-3 (mg/mL) were measured in duplicate by RIA pro-
vided by Nichols Institute Diagnostics. The sensitivity of the assay was
0.0625 mg/mL. The inter- and intraassay coefficients of variation were
between 5.3 and 6.3% and between 3.4 and 8.0%, respectively.
All samples from an individual subject were analyzed together.
The hormonal responses are expressed as absolute values. Sponta-
neous GH secretion was evaluated as mean GH concentration (mGHc)
calculated as the mean of individual GH levels from 0 up to 300 min.
The statistical analysis was carried out using nonparametric ANOVA
(Wilcoxon ANOVA test or Mann-Whitney test, where appropriate).
The results are expressed as mean 6 sem.
Results
Basal IGF-I levels in AN were lower than in NW (96.6 6
22.0 vs. 274.4 6 25.3 mg/L, P , 0.01).
After placebo administration, the mGHc, over 5 h, was
higher in AN than in NW (mGHc, 13.8 6 8.5 vs.1.8 6 0.6
mg/L; P , 0.01). Similarly, the peak GH response to GHRH
was higher in AN than in NW (30.1 6 3.7 vs. 20.6 6 2.9 mg/L,
P , 0.05).
rhIGF-I administration increased circulating IGF-I levels
in both groups (peak, 180.0 6 21.0 mg/L and 420.3 6 26.5
mg/L at 120 min in AN and NW, respectively; P , 0.05).
rhIGF-I-induced IGF-I levels remained rather constant from
120 min up to 300 min. The IGF-I percent increment was
similar in the two groups (86% and 77% in AN and NW),
despite rhIGF-I having induced lower IGF-I levels in AN
than in NW (P , 0.05) (Fig. 1).
rhIGF-I administration reduced mGHc in AN (6.8 6 3.2
mg/L, P , 0.01) but not in NW (1.6 6 0.3 mg/L). Neverthe-
less, mGHc in AN, after rhIGF-I, persisted at a higher level
than in NW (P , 0.05) (Fig. 1).
rhIGF-I administration inhibited the peak GH response to
GHRH in AN (21.3 6 4.1 mg/L, P , 0.05), as well as in NW
(13.1 6 4.5 mg/L, P , 0.05) (Fig. 2).
After rhIGF-I, the peak GH response to GHRH in AN
persisted at a level higher than in NW (P , 0.01) but became
similar to that recorded in NW after GHRH alone (Fig. 2).
Basal insulin (7.3 6 2.5 and 6.8 6 0.6 mU/L in AN and NW)
and glucose levels (70.6 6 5.6 and 74.9 6 5.7 mg/dL in AN
and NW) were similar in both groups. After rhIGF-I, insulin
levels showed a progressive decrease in AN (2.5 6 0.3 mU/L
at 300 min, P , 0.05) but not in NW (5.3 6 0.1 mU/L at 300
min) (Fig. 1).
In contrast, glucose levels were unaffected by rhIGF-I in
either group (66.5 6 2.0 and 73.9 6 3.7 mg/dL in AN and
NW) (Fig. 1).
Basal IGFBP-1 levels in AN and NW were similar (70.9 6
10.9 and 56.6 6 7.8 mg/L) and were increased (P , 0.05) by
rhIGF-I administration in both groups (215.1 6 45.5 and
TABLE 1. Clinical and hormonal details of patients with anorexia nervosa
Case
(n) Sex
Age
(yr)
BMI
(kg/m2)
Duration
of disease
(yr)
FSH
(U/L)
LH
(U/L)
E2
(nmol/L)
FT3
(pmol/L)
FT4
(pmol/L)
TSH
(mU/L)
Case 1 F 25 14.0 6.0 0.3 0.1 0.2 2.8 14.2 4.5
Case 2 F 21 12.8 3.0 0.2 0.1 0.1 0.9 11.7 1.2
Case 3 F 21 11.7 1.0 0.1 0.1 0.1 2.2 12.5 1.3
Case 4 F 29 13.7 8.0 0.5 0.3 0.2 2.4 11.3 1.1
Case 5 F 27 11.3 8.0 0.9 0.1 0.0 3.0 11.7 1.1
Case 6 F 18 16.7 2.0 3.0 0.8 0.0 3.2 9.4 1.8
Case 7 F 26 14.8 6.0 1.0 0.1 0.0 1.9 9.6 1.2
Case 8 F 19 16.2 2.0 0.3 1.4 0.0 2.4 11.2 0.9
Case 9 F 30 15.7 4.0 1.7 0.1 0.0 2.0 10.3 0.9
Mean 24.0 14.1 4.4 0.9 0.3 0.1 2.3 11.3 1.6
SD 1.5 0.6 0.9 0.3 0.2 0.0 0.2 0.5 0.4
SEM 1.4 0.6 0.8 0.3 0.1 0.0 0.2 0.5 0.4
E2, Estradiol; FT3, free T3; FT4, free T4; F, female.
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113 6 24.8 mg/L at 300 min), though attaining higher levels
in AN than in NW (P , 0.05).
Basal IGFBP-3 levels in AN were lower than in NW (3.6 6
0.5 vs. 6.6 6 0.5 mg/L, P , 0.05) and were not modified after
rhIGF-I administration (3.5 6 0.5 and 6.9 6 1.1 mg/L in AN
and NW).
Side effects
After rhIGF-I administration, some subjects in both groups
experienced transient discomfort at the injection site, but no
systemic side effects were observed. A transient facial flush-
ing after GHRH administration was also experienced by
most NW and by some AN patients.
Discussion
Our findings show that sc administration of a low rhIGF-I
dose, which restored circulating IGF-I levels within the nor-
mal range, inhibited both spontaneous and GHRH-stimu-
lated somatotroph secretion in patients with AN.
After rhIGF-I administration, the spontaneous GH secre-
tion, though significantly reduced, persisted at a level higher
than that in normal women, whereas the GH response to
GHRH in anorectic patients overlapped that found after
GHRH alone in controls.
In humans, the inhibitory effect of rhIGF-I on somatotroph
hypersecretion has been shown in Laron’s syndrome, IDDM,
malnutrition, and fasting (7, 8, 10, 24, 25). In healthy women,
a low rhIGF-I dose inhibited the GHRH- and, more mark-
edly, the GHRP-induced (but not the spontaneous) GH se-
cretion (13). Thus, the inhibitory IGF-I-effect on somatotroph
secretion is more evident in conditions of exaggerated GH
secretion, peripheral GH insensitivity, and low IGF-I levels
(19, 20, 23, 26). This proposition is consistent with our find-
ings in anorectic patients; in fact, even a low IGF-I dose
inhibited both spontaneous and stimulated GH secretion.
It is noteworthy, however, that in the anorectic patients of
our study, after rhIGF-I, both spontaneous and stimulated
GH secretion, though reduced, persisted at a level higher
than in normal women.
The inability of rhIGF-I administration to normalize so-
matotroph secretion in AN is worth noting. In fact, hyper-
sensitivity of IGF-I receptors in the median eminence during
food restriction (32) might have enhanced the IGF-I feedback
action in AN, a condition of GH resistance but IGF-I hyper-
sensitivity (33).
However, it must be noted that circulating IGF-I levels,
after rhIGF-I, in anorectic patients, though within the normal
range, were lower than those in normal women. Moreover,
in agreement with previous studies (34–36), we found that
in anorectic (but not in normal) subjects, rhIGF-I inhibited
insulin while increasing IGFBP-1 levels.
The rise in IGFBP-1 levels induced by hypoinsulinemia or
the direct stimulatory effect of rhIGF-I (36, 37) might reduce,
in turn, the bioactivity of free IGF-I and, hence, its inhibitory
feedback action, though coexistence of low IGFBP-3 levels
should balance this change (38).
Thus, our findings do not allow the conclusion that the
more marked GH secretion, the more marked the inhibitory
effect of rhIGF-I; whereas they rather suggest that GH hy-
persecretion in AN does not simply reflect reduction of the
negative IGF-I feedback action. In this context, the existence
of a state of GH resistance is supported by the finding of a
decreased circulating GH binding protein level in AN (19,
FIG. 1. Mean (6 SEM) serum IGF-I, GH, insulin, and plasma glucose
levels after placebo or rhIGF-I (20 mg/kg, sc at 0 min) in patients with
AN and in normal women.
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33), because GH binding protein represents the extracellular
domain of the GH receptor and is thought to reflect the GH
sensitivity (39).
There is evidence that the enhanced somatotroph secretion
in AN is the result of increased pulse frequency coupled with
enhanced tonic GH release (21, 22). However, both the pa-
rameters of GH pulsatility and the magnitude of the GHRH-
induced GH rise did not show any negative correlation with
IGF-I levels (21, 22); this further suggests that factors other
than, or in addition to, low IGF-I titers are responsible for the
altered GH secretion in this disease (see below).
This contention by no means rules out the potential impact
of malnutrition on the GH/IGF-I axis; in fact, besides re-
duction in circulating IGF-I levels, changes in IGFBPs and
metabolic inputs could exert a critical role (19, 33, 38, 40, 41).
It has to be pointed out, however, that in AN, primary al-
terations in the neuroendocrine control of somatotroph func-
tion have also been envisaged (17, 18, 21, 22, 26–28, 42, 43).
A primary hypothalamic GHRH hyperactivity, coupled
with a low SRIF tone, has been proposed to explain GH
hypersecretion (17, 18, 21, 22, 26–28, 42, 43), though SRIF
involvement has been questioned by other studies (44). An
altered neurohormonal control of somatotroph function
could, in turn, reflect changes occurring in the neurotrans-
mitter control (17, 18, 21, 27, 28, 42, 43).
In conclusion, this study shows that a low IGF-I dose
inhibits, though does not normalize, spontaneous and stim-
ulated GH secretion in AN.
These findings indicate that malnutrition-induced reduc-
tion of circulating IGF-I levels and its feedback action plays
an important role in the enhanced GH secretion of these
patients, though the existence of a hypothalamic dysregu-
lation can not be ruled out.
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